Court Rejects Motion To Declare Roche DNA Replication Technology Patents Unenforceable

Law360, New York (May 18, 2004, 12:00 AM EDT) -- A California U.S. District Court has refused to find Roche Diagnostics' portfolio of patents to its DNA replication technology unenforceable, dealing a setback to rival Promega in the decade-old battle over a technology widely used by medical and law enforcement officials.

But the court determined that Roche’s patent on the enzyme used by some practitioners to perform PCR, called "Taq," is unenforceable due to a finding of inequitable conduct.

Roche attorney Lanny J. Davis, a partner with Orrick, Herrington & Sutcliffe LLP, downplayed that determination, arguing...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.